Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2000

View Archived Issues

Sepracor reviews third quarter developments

Permax approved in Canada as monotherapy for PD

Aphios awarded grant for antiplaque research

Amylin moves AC-2993 to phase II for type 2 diabetes

Phase II trial results for Alprox-TD in ED announced by NexMed

New three-in-one approach to Parkinson's disease

SBIR grant awarded to MetaPhore for human septic shock study

Cistron and Celltech merger approved

Array BioPharma and Amgen to collaborate on phosphatase inhibitors

Merger of IGT Pharma and NTB creates new company focused on neuroprotection

Bayer seeks FDA approval for intravenous formulation of Avelox

Cilansetron moves into phase III for IBS

CPMP issues positive opinion for Prevenar

Maxamine protects against IL-2 toxicity in murine model

Effective dose range for MK-0663 in RA patients determined in large international trial

Casodex monotherapy associated with preservation of BMD and sexual interest

Enzo Biochem's oral HBV protein product highlighted at AASLD meeting

Preliminary clinical data on parenteral and oral BN-80915 presented at NCI-EORTC-AACR

Merck issued patent covering new anticoagulants

Selective factor Xa inhibitors designed by Cor Therapeutics researchers

Takara Shuzo identifies new anticancer tetrahydrofuran

Novel immunomodulators claimed by Abbott in patent literature

Roche's new antidiabetic agents act as glucokinase activators

New PDE3/4 inhibitors undergo extensive preclinical evaluation at Vernalis

Peptides from P&G are selective MC3 and/or MC4 receptor ligands

Neurogen discovers new series of compounds interacting with NK3 and/or GABA-A receptors

Preparation and use of aP2 inhibitors in diabetes and related conditions

GST P1-1-activated nitrogen mustard prodrug shows promise as cancer therapy

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026